← Back
Data updated: Mar 10, 2026
GENMAB US, INC.
OncologyMetabolicGastroenterology
GENMAB US, INC. is a biotechnology company focused on Oncology, Metabolic, Gastroenterology.
2023
Since
1
Drugs
-
Trials
3
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 98%
1 drugs Phase 3: 9 Phase 2: 7 Phase 1: 31
Metabolic 1%
0 drugs Phase 1: 1
Gastroenterology 1%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-05-19
- Latest
- 2025-11-18
- Applications
- 1